![The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model - eBioMedicine The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model - eBioMedicine](https://www.thelancet.com/cms/asset/f764ba59-5f27-4fbf-aeee-5bae3d1f7aa6/gr1.jpg)
The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model - eBioMedicine
![Solution‐Processed Two‐Dimensional MoS2 Nanosheets: Preparation, Hybridization, and Applications - Zhang - 2016 - Angewandte Chemie International Edition - Wiley Online Library Solution‐Processed Two‐Dimensional MoS2 Nanosheets: Preparation, Hybridization, and Applications - Zhang - 2016 - Angewandte Chemie International Edition - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/ffab09f4-ef56-4bd6-9c04-5ff38748e32b/anie201509933-toc-0001-m.png)
Solution‐Processed Two‐Dimensional MoS2 Nanosheets: Preparation, Hybridization, and Applications - Zhang - 2016 - Angewandte Chemie International Edition - Wiley Online Library
![Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial - The Lancet Oncology Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/d6622fb0-9069-436c-a3bd-a10885c23e2c/gr1.jpg)
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial - The Lancet Oncology
![RIG-I-induced innate antiviral immunity protects mice from lethal SARS-CoV-2 infection: Molecular Therapy - Nucleic Acids RIG-I-induced innate antiviral immunity protects mice from lethal SARS-CoV-2 infection: Molecular Therapy - Nucleic Acids](https://www.cell.com/cms/attachment/a2a8e2bf-06b9-4036-9b70-7707a878322f/fx1_lrg.jpg)
RIG-I-induced innate antiviral immunity protects mice from lethal SARS-CoV-2 infection: Molecular Therapy - Nucleic Acids
![Grid-Forming Control and Solar Curtailment | Evaluating Microgrid Control with Simscape Electrical, Part 2 Video - MATLAB & Simulink Grid-Forming Control and Solar Curtailment | Evaluating Microgrid Control with Simscape Electrical, Part 2 Video - MATLAB & Simulink](https://www.mathworks.com/videos/evaluating-microgrid-control-with-simscape-electrical-part-2-grid-forming-control-and-solar-curtailment-1655113773841/_jcr_content/thumbnail.adapt.1200.medium.jpg/1685429795043.jpg)
Grid-Forming Control and Solar Curtailment | Evaluating Microgrid Control with Simscape Electrical, Part 2 Video - MATLAB & Simulink
![Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method - The Lancet Infectious Diseases Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/7a138e08-16c3-41fd-8107-1fff8bb422f0/gr1.jpg)
Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method - The Lancet Infectious Diseases
![Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies - The Lancet Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies - The Lancet](https://www.thelancet.com/cms/attachment/8312cce9-0649-4da1-9ea6-fa80f2120e48/gr1.jpg)
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies - The Lancet
![Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis - The Lancet Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis - The Lancet](https://www.thelancet.com/cms/attachment/14dc13b0-bd83-4d16-8eee-da19a6b8acdc/gr1.jpg)
Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis - The Lancet
![Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study - The Lancet Microbe Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study - The Lancet Microbe](https://www.thelancet.com/cms/asset/fa17a484-040c-4399-bd32-b9b72e6e33ac/gr1.jpg)
Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study - The Lancet Microbe
![Vaccination of cats with Sad23L-nCoV-S vaccine candidate against major variants of SARS-CoV-2: Molecular Therapy - Methods & Clinical Development Vaccination of cats with Sad23L-nCoV-S vaccine candidate against major variants of SARS-CoV-2: Molecular Therapy - Methods & Clinical Development](https://www.cell.com/cms/attachment/4d7dd4a7-b606-4fb0-91a7-81f36eebe6b0/fx1.jpg)